Corcept Therapeutics Incorporated $CORT Stock Purchased by Vise Technologies Inc.

Vise Technologies Inc. boosted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 91.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,901 shares of the biotechnology company’s stock after buying an additional 8,535 shares during the period. Vise Technologies Inc.’s holdings in Corcept Therapeutics were worth $2,063,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Summit Global Investments purchased a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $1,382,000. State of Wyoming purchased a new position in Corcept Therapeutics during the 3rd quarter worth approximately $182,000. Parcion Private Wealth LLC purchased a new position in Corcept Therapeutics during the 3rd quarter worth approximately $420,000. Choreo LLC grew its position in Corcept Therapeutics by 8.0% during the 3rd quarter. Choreo LLC now owns 4,190 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 312 shares in the last quarter. Finally, Motley Fool Asset Management LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter valued at $403,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Joseph Lyon sold 9,190 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $116.13, for a total value of $1,067,234.70. Following the completion of the transaction, the insider owned 5,683 shares in the company, valued at approximately $659,966.79. The trade was a 61.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James Wilson sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $114.81, for a total value of $1,148,100.00. Following the completion of the transaction, the director directly owned 1,054,543 shares in the company, valued at $121,072,081.83. The trade was a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 382,536 shares of company stock worth $43,406,554. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Third-quarter revenue climbed 64% year over year to about $340.5 million, while earnings of $1.01 per share beat estimates. Higher Korlym sales and growing Lifyorli uptake contributed to the results. Article: CORT’s Q3 Earnings Beat
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. Article: Piper Sandler rating
• Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s revenue by 2030; both depend on regulatory and commercial success. Article: Relacorilant decision and revenue target
• Negative Sentiment: Shares have faced pressure despite the earnings beat as investors focused on company guidance. HC Wainwright also lowered its Q1 2027 EPS estimate to $0.60 from $0.74, although it kept a Buy rating and $165 price target. Article: Shares fall on guidance
• Negative Sentiment: Two insiders reported sizable sales: Roberto Vieira sold 8,333 shares, reducing his position by about 68%, while Sean Maduck sold shares in two transactions that cut his holdings by more than half. Insider sales can raise concerns, though they do not necessarily indicate a change in company prospects. Article: Corcept insider sale

Corcept Therapeutics Stock Down 9.6%

CORT stock opened at $71.63 on Friday. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $126.38. The company has a market cap of $7.84 billion, a price-to-earnings ratio of 56.40 and a beta of 0.54. The company has a 50 day moving average of $108.46 and a two-hundred day moving average of $75.47.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The company had revenue of $340.47 million for the quarter, compared to the consensus estimate of $339.12 million. During the same period in the previous year, the business earned $0.16 earnings per share. The company’s quarterly revenue was up 64.0% on a year-over-year basis. On average, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.83 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Weiss Ratings raised Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Zacks Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Truist Financial assumed coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price objective for the company. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $139.50.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.